Back to Search
Start Over
Effectiveness of homologous or heterologous immunization regimens against SARS-CoV-2 after two doses of inactivated COVID-19 vaccine: A systematic review and meta-analysis
- Source :
- Human Vaccines & Immunotherapeutics, Vol 19, Iss 2 (2023)
- Publication Year :
- 2023
- Publisher :
- Taylor & Francis Group, 2023.
-
Abstract
- We aimed to evaluate the effectiveness or efficacy of heterologous or homologous COVID-19 vaccine regimens against COVID-19-related outcomes after primary immunization with two doses of CoronaVac or Sinopharm COVID-19 vaccines. PubMed, EMBASE, Web of Science, and Cochrane Library databases were searched up to 31 October 2022. The primary measure was vaccine effectiveness against COVID-19 infection with homologous or heterologous booster. The results showed heterologous and homologous booster significantly improved effectiveness against COVID-19 infection compared to primary immunization. The effectiveness against COVID-19 infection was 89.19% (95%CI 78.49, 99.89) for heterologous mRNA vaccine booster, 87.00% (95%CI 82.14, 91.85) for non-replicating vector vaccine booster, 69.99% (95%CI 52.16, 87.82) for homologous booster, and 51.48% (95%CI 41.75, 61.21) for two doses of inactivated vaccine. Homologous and heterologous regimens were also effective against SARS-CoV-2 variants, and more evidence is still needed to confirm our findings.
Details
- Language :
- English
- ISSN :
- 21645515 and 2164554X
- Volume :
- 19
- Issue :
- 2
- Database :
- Directory of Open Access Journals
- Journal :
- Human Vaccines & Immunotherapeutics
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.7950ea9b929844afa85a1585dcfa1364
- Document Type :
- article
- Full Text :
- https://doi.org/10.1080/21645515.2023.2221146